these guys must all be dummies!
Several large investors have recently modified their holdings of ACRX. BlackRock Inc. boosted its stake in AcelRx Pharmaceuticals by 3.4% during the 4th quarter. BlackRock Inc. now owns 5,640,946 shares of the specialty pharmaceutical company’s stock worth $6,995,000 after purchasing an additional 185,924 shares during the last quarter. Morgan Stanley lifted its stake in AcelRx Pharmaceuticals by 30.4% in the 3rd quarter. Morgan Stanley now owns 801,424 shares of the specialty pharmaceutical company’s stock worth $1,138,000 after purchasing an additional 186,993 shares in the last quarter. Wells Fargo & Company MN grew its position in shares of AcelRx Pharmaceuticals by 54.3% in the fourth quarter. Wells Fargo & Company MN now owns 316,632 shares of the specialty pharmaceutical company’s stock valued at $393,000 after purchasing an additional 111,399 shares in the last quarter. GSA Capital Partners LLP increased its holdings in shares of AcelRx Pharmaceuticals by 28.9% in the fourth quarter. GSA Capital Partners LLP now owns 203,830 shares of the specialty pharmaceutical company’s stock valued at $253,000 after purchasing an additional 45,656 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in AcelRx Pharmaceuticals by 8.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 202,469 shares of the specialty pharmaceutical company’s stock worth $252,000 after buying an additional 15,060 shares during the last quarter. 24.45% of the stock is currently owned by hedge funds and other institutional investors.
